Encompass Health Corporation (NYSE:EHC - Free Report) - Equities researchers at Zacks Research upped their FY2026 earnings estimates for shares of Encompass Health in a research note issued to investors on Wednesday, November 18th. Zacks Research analyst Team now anticipates that the company will post earnings of $6.24 per share for the year, up from their previous estimate of $6.03. The consensus estimate for Encompass Health's current full-year earnings is $6.29 per share. Zacks Research also issued estimates for Encompass Health's Q4 2026 earnings at $1.57 EPS, Q1 2027 earnings at $1.67 EPS, Q2 2027 earnings at $1.69 EPS, Q3 2027 earnings at $1.58 EPS, Q4 2027 earnings at $1.71 EPS, FY2027 earnings at $6.65 EPS, Q1 2028 earnings at $1.81 EPS, Q2 2028 earnings at $1.94 EPS, Q3 2028 earnings at $1.80 EPS and FY2028 earnings at $7.44 EPS.
Several other equities analysts also recently issued reports on the stock. Mizuho set a $155.00 price objective on shares of Encompass Health in a research note on Monday, November 2nd. Truist Financial reiterated a "buy" rating and set a $156.00 target price (up from $150.00) on shares of Encompass Health in a report on Friday, October 30th. Weiss Ratings raised shares of Encompass Health from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Raymond James Financial reissued a "strong-buy" rating and set a $155.00 target price on shares of Encompass Health in a research report on Friday, October 30th. Finally, TD Cowen boosted their price objective on shares of Encompass Health from $140.00 to $150.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company's stock. According to MarketBeat, Encompass Health presently has a consensus rating of "Buy" and a consensus target price of $154.25.
Read Our Latest Analysis on Encompass Health
Encompass Health Price Performance
Shares of NYSE:EHC opened at $134.93 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.09 and a current ratio of 1.09. Encompass Health has a one year low of $92.77 and a one year high of $143.90. The business's fifty day moving average price is $127.72 and its two-hundred day moving average price is $112.68. The stock has a market cap of $13.24 billion, a PE ratio of 21.08, a price-to-earnings-growth ratio of 2.39 and a beta of 0.83.
Encompass Health (NYSE:EHC - Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.36 by $0.16. Encompass Health had a return on equity of 18.35% and a net margin of 10.17%. The company had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the business earned $1.23 earnings per share. Encompass Health's quarterly revenue was up 8.9% compared to the same quarter last year.
Encompass Health Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Monday, January 4th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, January 4th. Encompass Health's payout ratio is currently 13.12%.
Insider Activity at Encompass Health
In other Encompass Health news, EVP John Darby sold 4,858 shares of the business's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $121.09, for a total transaction of $588,255.22. Following the transaction, the executive vice president owned 75,041 shares in the company, valued at $9,086,714.69. The trade was a 6.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.80% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Encompass Health
Large investors have recently modified their holdings of the stock. Diversify Wealth Management LLC lifted its position in Encompass Health by 94.6% during the 3rd quarter. Diversify Wealth Management LLC now owns 10,758 shares of the company's stock worth $1,374,000 after acquiring an additional 5,231 shares in the last quarter. Diversify Advisory Services LLC boosted its holdings in Encompass Health by 93.8% in the 3rd quarter. Diversify Advisory Services LLC now owns 10,714 shares of the company's stock worth $1,302,000 after acquiring an additional 5,187 shares during the period. Allworth Financial LP grew its position in Encompass Health by 22.0% in the third quarter. Allworth Financial LP now owns 1,511 shares of the company's stock valued at $184,000 after acquiring an additional 272 shares in the last quarter. Toronto Dominion Bank acquired a new stake in Encompass Health in the third quarter valued at approximately $21,846,000. Finally, Integral Health Asset Management LLC purchased a new stake in shares of Encompass Health during the third quarter valued at approximately $14,579,000. Institutional investors and hedge funds own 97.25% of the company's stock.
Encompass Health News Roundup
These are some of the EHC news items that stood out recently:
- Positive Sentiment: Zacks Research increased its full-year EPS estimates to $6.24 for 2026 (from $6.03), $6.65 for 2027 (from $6.42), and $7.44 for 2028 (from $7.18). It also raised estimates for several quarters through 2028, pointing to stronger projected earnings. Encompass Health analyst estimates
- Positive Sentiment: A recent Zacks article highlighted Encompass Health’s operating growth, improving profitability outlook, capacity expansion and shareholder initiatives as factors behind its strong year-to-date performance. Zacks article on Encompass Health’s performance
- Neutral Sentiment: Zacks’ 2026 EPS forecast of $6.24 remains slightly below the cited consensus estimate of $6.29, so the upward revisions do not necessarily signal that broader analyst expectations have moved higher.
About Encompass Health
(
Get Free Report)
Encompass Health Corporation is a U.S. healthcare provider focused on inpatient rehabilitation. The company operates rehabilitation hospitals that offer specialized care for people recovering from conditions such as strokes, brain and spinal cord injuries, orthopedic conditions, and other illnesses or injuries. Its hospitals provide coordinated rehabilitation services, including physical, occupational, and speech therapy, alongside medical care. Encompass Health serves patients through facilities across the United States.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.